Caverject is administered via small-needle injection into an area of the penis known as the corpus cavernosum. It works by relaxing smooth muscle tissue which, in turn, enhances blood flow to the penis, creating an erection. The drug is indicated for the treatment of erectile dysfunction whether the cause is neurological, vascular, psychological or of mixed origin. Patients selected for treatment with Caverject receive initial injections from medically-trained personnel to determine optimum dosing. Caverject can be administered by the patient once he has been trained to self-inject.
Approximately 200 reports exist in published literature on self- injection therapy with alprostadil. Results from clinical trials showed that more than 80 percent of patients diagnosed with erectile dysfunction who used Caverject experienced an erection.
Caverject and the Patient
The availability of Caverject could have a significant impact on the lives of patients and their partners.
"For many men, impotence is a source of extreme emotional frustration, embarrassment and loss of self-esteem," said J. Francois Eid, who conducted clinical trials with the drug for Upjohn. "Caverject represents new hope for the many impotent men and their partners currently suffering in silence. It also represents an important new treatment option for those impotent men not satisfied with their current therapy."
The Origins of Caverject
Caverject contains prostaglandin E1 (alprostadil), a vasoactive agent that, in a different formulation, has been used as a pre-surgical treatment for infants with congenital heart defects. Prostaglandins occur naturally in human tissues and fluids and play a role in the mechanism of natural erection. Caverject is administered via injection into the penis, using a syringe with a small needle.
In clinical studies, the most common side effect of Caverject was penile pain (37 percent). Other less common side effects include injection site bleeding (5 percent), prolonged erection of four to six hours (4 percent), and fibrosis (3 percent, with one, 18-month study recording a rate of 7.8 percent). The incidence of priapism, an erection that lasts more than six hours, was 0.4 percent.
Caverject is indicated for the treatment of erectile dysfunction whether the cause is neurological, vascular, psychological or of mixed origin. It is self-injected into the penis shortly before sexual intercourse. Caveject creates an erection by relaxing the smooth muscle tissue and dilating the major artery in the penis, which enhances the blood flow to the penis.
Upon order, You will receive injectable (Formebolone) Caverject by UpJohn.